1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legislation

After Seven Years Device Tax Repeal Looks Certain

US lawmakers have agreed on a bipartisan budget to prevent a government shutdown that includes repealing the medical device tax. If all goes according to plan, the bill -- which was approved by the House on 17 December and is now headed to the Senate -- is expected to be on the president’s desk for signing by the end of the week.

United States Capitol on 50 Dollars bill USA money banknote

Almost seven years after it went into effect, the medical device excise tax that has haunted the medtech industry is close to an end. US lawmakers released a last-minute budget agreement to avoid a potential government shutdown that includes a full repeal of the tax and has a high likelihood of passing. By mid-day on 19 December, the consolidated Appropriations bill containing the device tax repeal provision was approved by the US House of Representatives and the Senate, and was headed to President's desk to be signed.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

No FDA Reorg Planned, Makary Says

 
• By Elizabeth Orr

FDA Commissioner Marty Makary stated in a new interview that there will be no significant reorganization of the agency, despite earlier reports. Using his “guiding principles” of common sense and gold-standard science, he plans to focus on reforms including improved pathways for medical AI and food safety as well as addressing employee morale.

Medtech Seeks Inclusion In EU’s Groundbreaking Life Sciences Strategy

 
• By Amanda Maxwell

As the EU Life Sciences Strategy aims to drive innovation, the medtech sector is pushing for a pivotal role in a mission intended to embrace green and digital transitions, address regulatory obstacles and reduce dependency on external sources.

Former FDA Head Tells Heart Society To ‘Get Involved’ To Protect Health Innovation

 
• By Elizabeth Orr

Former FDA Commissioner Robert Califf urged the Heart Rhythm Society to engage actively amid federal funding cuts. He highlighted collaboration among researchers, advocates for healthcare integration, and the importance of addressing social determinants of health, while discussing lobbying strategies and the challenges faced by medtech companies.